BMO Capital Markets Issues Pessimistic Forecast for Medpace (NASDAQ:MEDP) Stock Price

Medpace (NASDAQ:MEDP) had its price objective decreased by equities researchers at BMO Capital Markets from $460.00 to $400.00 in a research report issued on Friday, MarketBeat reports. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ target price suggests a potential downside of 2.57% from the company’s current price.

A number of other analysts have also recently commented on the stock. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and cut their price target for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Leerink Partners cut their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Robert W. Baird cut their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday. Barclays cut their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $467.08.

Medpace Trading Up 4.4%

Shares of MEDP opened at $410.54 on Friday. Medpace has a 12 month low of $284.10 and a 12 month high of $628.92. The firm has a fifty day simple moving average of $470.61 and a 200 day simple moving average of $535.75. The stock has a market capitalization of $11.73 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 1.85 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the prior year, the company posted $3.67 earnings per share. The firm’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts predict that Medpace will post 17.05 earnings per share for the current fiscal year.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Trading of Medpace

Hedge funds have recently modified their holdings of the stock. Quent Capital LLC acquired a new stake in shares of Medpace during the 3rd quarter worth about $25,000. Optiver Holding B.V. acquired a new stake in shares of Medpace during the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace during the 4th quarter worth about $30,000. Finally, Elyxium Wealth LLC bought a new position in Medpace during the fourth quarter worth about $30,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 beat and raised outlook — Medpace reported Q1 EPS of $4.28 and revenue of $706.6M, both above consensus, and gave FY2026 EPS guidance of $16.68–$17.50. Strong revenue growth and guidance are the primary bullish catalyst. Article Title
• Positive Sentiment: Analyst support remains — Robert W. Baird kept an Outperform rating with a $477 target (still implying upside), providing some analyst backing despite volatility. Article Title
• Positive Sentiment: Technical/buy‑the‑dip narratives — Some outlets note MEDP moved into oversold territory after recent selling, which can attract short‑term bargain hunters. Article Title
• Neutral Sentiment: Short‑interest data unclear — April short‑interest reporting shows effectively 0 days to cover based on the provided figure, an anomalous data point that appears neutral until clarified by exchanges/brokers.
• Neutral Sentiment: Backlog conversion but rising cancellations — Management highlighted roughly $1.94B of backlog conversion over 12 months, but cancellation rates have increased; this is a mixed operational signal that could either load revenue or indicate instability in bookings. Article Title
• Negative Sentiment: Multiple securities‑fraud class action notices filed and law‑firm solicitations — Several firms have announced lawsuits and are soliciting lead‑plaintiff motions with a June 8, 2026 deadline, increasing legal and investor‑sentiment risk. This is a material near‑term overhang. Article Title
• Negative Sentiment: Analyst caution and downgrades tied to cancellations/elevated costs — Some analysts cut stance or reduced price targets citing the spike in backlog cancellations and higher direct costs (e.g., Seeking Alpha coverage and a BMO price‑target cut to $400), which can pressure sentiment and valuation. Article Title
• Negative Sentiment: Executive departure — Medpace’s president announced his resignation after 18 years, adding leadership transition risk at a sensitive time. Article Title

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.